“…Other anti-asthmatic treatments, both prior to and after start of omalizumab treatment, were included in twelve of these studies (28, 30-33, 35, 37, 42, 44, 45, 48, 49). The most common clinical outcome, included in 14 studies, was FEV1 (28,32,34,35,37,39,42,43,(45)(46)(47)(48)(49)(50). Fewer studies reported on other objective (32,34,39,46,49,50) and subjective (29,41) (37,42,50)), and work or school days lost due to asthma (29,32,37,44).…”